Efficacy and safety of clozapine and olanzapine: an open-label study comparing two groups of Parkinson's disease patients with dopaminergic-induced psychosis
Identifieur interne : 001A75 ( Main/Exploration ); précédent : 001A74; suivant : 001A76Efficacy and safety of clozapine and olanzapine: an open-label study comparing two groups of Parkinson's disease patients with dopaminergic-induced psychosis
Auteurs : S. Giménez-Roldán [Espagne] ; D. Mateo [Espagne] ; E. Navarro [Espagne] ; M. M Ginés [Espagne]Source :
- Parkinsonism and Related Disorders [ 1353-8020 ] ; 2000.
English descriptors
- KwdEn :
Abstract
Clozapine, an atypical neuroleptic agent, improves dopaminergic-induced psychosis in parkinsonian patients without increasing motor disability. However, because of the risk of agranulocytosis periodic hematological controls are mandatory. Olanzapine, another atypical neuroleptic, does not require such monitoring, which may represent a practical advantage. Therefore, for 12weeks we compared the tolerability and efficacy of clozapine and olanzapine in two groups of nine consecutive parkinsonian psychotic patients treated with these compounds. All the patients on clozapine (mean starting dose: 13.1±7.9mg/d) completed the study despite reporting a number of adverse events, including somnolence, falls, orthostatic hypotension, and syncope. In contrast, early withdrawal occurred in three of the nine patients receiving olanzapine, due to severe gait deterioration and drowsiness (mean starting dose: 3.9±1.3mg/d). Psychotic symptoms improved in both groups, as reflected by a reduction of 71.7% in clozapine and a 61.7% reduction in olanzapine, in five selected items from the Neuropsychiatric Inventory. On conclusion of the study, parkinsonism had improved in the clozapine group with a 19.7% decrease in the raw scores and a 7.9% decrease in the weighted scores according to the Cornell University Rating Scale for parkinsonism (mean dose: 16.9± 10.3mg/d). Conversely, the six patients receiving olanzapine who finished the study experienced aggravated parkinsonian symptoms, with a 25.5% worsening in the raw scores and a 24.6% worsening in the weighted scores (mean dose: 4.7±2.3mg/d). We postulate that the early drop-outs in the olanzapine-treated parkinsonian group may be attributable to a non-specific effect of the drug as a result of starting at too high a dose, and that the worsening of parkinsonism following prolonged treatment may have been caused by the drug's blocking effect on striatal D2 receptors.
Url:
DOI: 10.1016/S1353-8020(00)00024-9
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Efficacy and safety of clozapine and olanzapine: an open-label study comparing two groups of Parkinson's disease patients with dopaminergic-induced psychosis</title><author><name sortKey="Gimenez Roldan, S" sort="Gimenez Roldan, S" uniqKey="Gimenez Roldan S" first="S" last="Giménez-Roldán">S. Giménez-Roldán</name></author><author><name sortKey="Mateo, D" sort="Mateo, D" uniqKey="Mateo D" first="D" last="Mateo">D. Mateo</name></author><author><name sortKey="Navarro, E" sort="Navarro, E" uniqKey="Navarro E" first="E" last="Navarro">E. Navarro</name></author><author><name sortKey="Gines, M M" sort="Gines, M M" uniqKey="Gines M" first="M. M" last="Ginés">M. M Ginés</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:E8EACE415B98708F332BA6F2025C41C90970CC06</idno><date when="2001" year="2001">2001</date><idno type="doi">10.1016/S1353-8020(00)00024-9</idno><idno type="url">https://api.istex.fr/document/E8EACE415B98708F332BA6F2025C41C90970CC06/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">001494</idno><idno type="wicri:Area/Main/Curation">001273</idno><idno type="wicri:Area/Main/Exploration">001A75</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Efficacy and safety of clozapine and olanzapine: an open-label study comparing two groups of Parkinson's disease patients with dopaminergic-induced psychosis</title><author><name sortKey="Gimenez Roldan, S" sort="Gimenez Roldan, S" uniqKey="Gimenez Roldan S" first="S" last="Giménez-Roldán">S. Giménez-Roldán</name><affiliation wicri:level="2"><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Neurology, Hospital General Universitario Gregorio Marañón, Servicio de Neurologia, Doctor Esquerdo 46, 28007 Madrid</wicri:regionArea><placeName><region nuts="2" type="communauté">Communauté de Madrid</region></placeName></affiliation><affiliation wicri:level="1"><country wicri:rule="url">Espagne</country></affiliation></author><author><name sortKey="Mateo, D" sort="Mateo, D" uniqKey="Mateo D" first="D" last="Mateo">D. Mateo</name><affiliation wicri:level="2"><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Neurology, Hospital General Universitario Gregorio Marañón, Servicio de Neurologia, Doctor Esquerdo 46, 28007 Madrid</wicri:regionArea><placeName><region nuts="2" type="communauté">Communauté de Madrid</region></placeName></affiliation></author><author><name sortKey="Navarro, E" sort="Navarro, E" uniqKey="Navarro E" first="E" last="Navarro">E. Navarro</name><affiliation wicri:level="2"><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Neurology, Hospital General Universitario Gregorio Marañón, Servicio de Neurologia, Doctor Esquerdo 46, 28007 Madrid</wicri:regionArea><placeName><region nuts="2" type="communauté">Communauté de Madrid</region></placeName></affiliation></author><author><name sortKey="Gines, M M" sort="Gines, M M" uniqKey="Gines M" first="M. M" last="Ginés">M. M Ginés</name><affiliation wicri:level="2"><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Neurology, Hospital General Universitario Gregorio Marañón, Servicio de Neurologia, Doctor Esquerdo 46, 28007 Madrid</wicri:regionArea><placeName><region nuts="2" type="communauté">Communauté de Madrid</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Parkinsonism and Related Disorders</title><title level="j" type="abbrev">PRD</title><idno type="ISSN">1353-8020</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="2000">2000</date><biblScope unit="volume">7</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="121">121</biblScope><biblScope unit="page" to="127">127</biblScope></imprint><idno type="ISSN">1353-8020</idno></series><idno type="istex">E8EACE415B98708F332BA6F2025C41C90970CC06</idno><idno type="DOI">10.1016/S1353-8020(00)00024-9</idno><idno type="PII">S1353-8020(00)00024-9</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1353-8020</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Atypical neuroleptics</term><term>Clozapine</term><term>Dopaminergic-induced psychosis</term><term>Olanzapine</term><term>Parkinson's disease (PD)</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Clozapine, an atypical neuroleptic agent, improves dopaminergic-induced psychosis in parkinsonian patients without increasing motor disability. However, because of the risk of agranulocytosis periodic hematological controls are mandatory. Olanzapine, another atypical neuroleptic, does not require such monitoring, which may represent a practical advantage. Therefore, for 12weeks we compared the tolerability and efficacy of clozapine and olanzapine in two groups of nine consecutive parkinsonian psychotic patients treated with these compounds. All the patients on clozapine (mean starting dose: 13.1±7.9mg/d) completed the study despite reporting a number of adverse events, including somnolence, falls, orthostatic hypotension, and syncope. In contrast, early withdrawal occurred in three of the nine patients receiving olanzapine, due to severe gait deterioration and drowsiness (mean starting dose: 3.9±1.3mg/d). Psychotic symptoms improved in both groups, as reflected by a reduction of 71.7% in clozapine and a 61.7% reduction in olanzapine, in five selected items from the Neuropsychiatric Inventory. On conclusion of the study, parkinsonism had improved in the clozapine group with a 19.7% decrease in the raw scores and a 7.9% decrease in the weighted scores according to the Cornell University Rating Scale for parkinsonism (mean dose: 16.9± 10.3mg/d). Conversely, the six patients receiving olanzapine who finished the study experienced aggravated parkinsonian symptoms, with a 25.5% worsening in the raw scores and a 24.6% worsening in the weighted scores (mean dose: 4.7±2.3mg/d). We postulate that the early drop-outs in the olanzapine-treated parkinsonian group may be attributable to a non-specific effect of the drug as a result of starting at too high a dose, and that the worsening of parkinsonism following prolonged treatment may have been caused by the drug's blocking effect on striatal D2 receptors.</div></front></TEI><affiliations><list><country><li>Espagne</li></country><region><li>Communauté de Madrid</li></region></list><tree><country name="Espagne"><region name="Communauté de Madrid"><name sortKey="Gimenez Roldan, S" sort="Gimenez Roldan, S" uniqKey="Gimenez Roldan S" first="S" last="Giménez-Roldán">S. Giménez-Roldán</name></region><name sortKey="Gimenez Roldan, S" sort="Gimenez Roldan, S" uniqKey="Gimenez Roldan S" first="S" last="Giménez-Roldán">S. Giménez-Roldán</name><name sortKey="Gines, M M" sort="Gines, M M" uniqKey="Gines M" first="M. M" last="Ginés">M. M Ginés</name><name sortKey="Mateo, D" sort="Mateo, D" uniqKey="Mateo D" first="D" last="Mateo">D. Mateo</name><name sortKey="Navarro, E" sort="Navarro, E" uniqKey="Navarro E" first="E" last="Navarro">E. Navarro</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001A75 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001A75 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:E8EACE415B98708F332BA6F2025C41C90970CC06
|texte= Efficacy and safety of clozapine and olanzapine: an open-label study comparing two groups of Parkinson's disease patients with dopaminergic-induced psychosis
}}
| This area was generated with Dilib version V0.6.23. |  |